Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any inherited retinal dystrophy in which the cause of the disease is a mutation in the GUCY2D gene.
Biomarker and diagnostic research for GUCY2D retinopathy has been reported in the published literature.
No clinical trials have been registered for GUCY2D retinopathy.
19 publications have been identified in PubMed for GUCY2D retinopathy. Research spans Basic Science / Preclinical (42%), Review / Meta-Analysis (16%), and Clinical Trial Publication (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 8 | 42% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 4:29 PM UTC
Common questions about GUCY2D retinopathy
3 |
16% |
Clinical study results | 3 | 16% |
Disease patterns and progression | 3 | 16% |
Testing and diagnosis research | 1 | 5% |
New treatment approaches | 1 | 5% |
Barberán-Martínez P (2026). [PMID: 41500401](https://pubmed.ncbi.nlm.nih.gov/41500401/). *The Journal of molecular diagnostics : JMD*. [Diagnostic / Biomarker]
Sanders F (2025). [PMID: 40541286](https://pubmed.ncbi.nlm.nih.gov/40541286/). *The British journal of ophthalmology*. [Epidemiology / Natural History]
Wong WM (2025). [PMID: 40013354](https://pubmed.ncbi.nlm.nih.gov/40013354/). *Clinical & experimental ophthalmology*. [Clinical Trial Publication]
Guareschi BLV (2025). [PMID: 41012804](https://pubmed.ncbi.nlm.nih.gov/41012804/). *Veterinary sciences*. [Basic Science / Preclinical]
Ba-Abbad R (2025). [PMID: 40478561](https://pubmed.ncbi.nlm.nih.gov/40478561/). *Investigative ophthalmology & visual science*. [Clinical Trial Publication]
Liu C (2025). [PMID: 41153400](https://pubmed.ncbi.nlm.nih.gov/41153400/). *Genes*. [Clinical Trial Publication]
Upadhyaya A (2025). [PMID: 39728598](https://pubmed.ncbi.nlm.nih.gov/39728598/). *Indian journal of ophthalmology*. [Epidemiology / Natural History]
Dizhoor AM (2025). [PMID: 39909376](https://pubmed.ncbi.nlm.nih.gov/39909376/). *The Journal of biological chemistry*. [Basic Science / Preclinical]
Fang XH (2025). [PMID: 40688792](https://pubmed.ncbi.nlm.nih.gov/40688792/). *International journal of ophthalmology*. [Basic Science / Preclinical]
Sao Su S (2025). [PMID: 40101946](https://pubmed.ncbi.nlm.nih.gov/40101946/). *Ophthalmic genetics*. [Epidemiology / Natural History]
AI-curated news mentioning GUCY2D retinopathy
Updated Jun 8, 2026
A rare case study highlights a multisystem autoimmune disease that emerged with symptoms of retinopathy and alopecia following COVID-19 vaccination. This finding contributes to the understanding of potential post-vaccination autoimmune responses.